ES2159693T3 - Ligandos 5ht1dalfa y 5ht2a. - Google Patents

Ligandos 5ht1dalfa y 5ht2a.

Info

Publication number
ES2159693T3
ES2159693T3 ES96309200T ES96309200T ES2159693T3 ES 2159693 T3 ES2159693 T3 ES 2159693T3 ES 96309200 T ES96309200 T ES 96309200T ES 96309200 T ES96309200 T ES 96309200T ES 2159693 T3 ES2159693 T3 ES 2159693T3
Authority
ES
Spain
Prior art keywords
sub
rent
sup
hydrogen
alcoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96309200T
Other languages
English (en)
Inventor
Peter Thaddeus Gallagher
William Martin Owton
Colin William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of ES2159693T3 publication Critical patent/ES2159693T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPUESTO FARMACEUTICO DE FORMULA EN DONDE R 1 Y R SUP,2} SON CADA UNO HIDROGENO, ALQUILO C{SUB,1-4}, ALCOXI C{SUB,1-4}, HO-ALQUILO C{SUB,1-4}, ALCOXI C{SUB,1-4}ALQUILO C{SUB,1-4}, ALQUILTIO C{SUB,1-4}, HALO O PHCR''R''''- DONDE PH ES FENILO OPCIONALMENTE SUSTITUIDO Y R'' Y R'''' SON CADA UNO HIDROGENO O ALQUILO C{SUB,1-4}, O R{SUP,1} Y R{SUP,2} JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS, FORMAN UN GRUPO CICLOALQUILO C{SUB,3-6}, R{SUP,3}, R{SUP,4} Y R{SUP,5} SON CADA UNO HIDROGENO, HALO, NITRO, ALQUILO C{SUB,1-4}, ALCOXI C{SUB,1-4}, ALQUILTIO C{SUB,14}, ALQUIL C{SUB,1-4}-CO-, ALQUIL C{SUB,1-4}-S(O){SUB,M}- DONDE M ES 0,1 O 2, R''R''''N-SO{SUB,2}-, -COOR'', -CONR''R'''', -NR''R'''', N(OR'')COOR'''', -COR'', -NHSO{SUB,2}R'', DONDE R'' Y R'''' SON CADA UNO HIDROGENO, O ALQUILO C{SUB,1-4}, R{SUP,6} Y R{SUP,7} SON CADA UNO HIDROGENO O ALQUILO C{SUB,1-4}, Y N ES DE 1 A 6, X ES OXIGENO O AZUFRE, W ES DONDE P ES DE 4 A 7, Y Q Y R SON CADA UNO DE 1 A 3, Y ES Y Z ES FENILO OPCIONALMENTE SUSTITUIDO O HETEROARILO OPCIONALMENTE SUSTITUIDO; Y SALES Y ESTERES DE DICHOS COMPUESTOS.
ES96309200T 1995-12-19 1996-12-17 Ligandos 5ht1dalfa y 5ht2a. Expired - Lifetime ES2159693T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9525963A GB2308362A (en) 1995-12-19 1995-12-19 Pharmaceutical indole derivatives

Publications (1)

Publication Number Publication Date
ES2159693T3 true ES2159693T3 (es) 2001-10-16

Family

ID=10785702

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96309200T Expired - Lifetime ES2159693T3 (es) 1995-12-19 1996-12-17 Ligandos 5ht1dalfa y 5ht2a.

Country Status (27)

Country Link
US (1) US5773448A (es)
EP (1) EP0780388B1 (es)
JP (1) JPH09202784A (es)
KR (1) KR970042503A (es)
CN (1) CN1157822A (es)
AR (1) AR010205A1 (es)
AT (1) ATE204273T1 (es)
AU (1) AU720711B2 (es)
BR (1) BR9606066A (es)
CA (1) CA2193039C (es)
CZ (1) CZ372296A3 (es)
DE (1) DE69614491T2 (es)
DK (1) DK0780388T3 (es)
ES (1) ES2159693T3 (es)
GB (1) GB2308362A (es)
HU (1) HUP9603498A3 (es)
IL (1) IL119844A (es)
MX (1) MX9606531A (es)
NO (1) NO307512B1 (es)
NZ (1) NZ299959A (es)
PE (1) PE26198A1 (es)
PL (1) PL317526A1 (es)
PT (1) PT780388E (es)
SG (1) SG47206A1 (es)
TR (1) TR199601018A1 (es)
YU (1) YU67096A (es)
ZA (1) ZA9610589B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN106928122A (zh) * 2017-03-07 2017-07-07 贵州大学 3‑烷氧基季碳氧化吲哚及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4035369A (en) * 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
US4432978A (en) * 1979-07-30 1984-02-21 Pfizer Inc. Hexahydro-trans-pyridoindole
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
FR2523964B1 (fr) * 1982-03-23 1985-09-27 Sanofi Sa Nouveaux derives de la tryptamine actifs notamment sur le systeme cardiovasculaire et procede pour leur preparation
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
US4658038A (en) * 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
US4608374A (en) * 1983-11-07 1986-08-26 Hoechst-Roussel Pharmaceuticals Inc. 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents
GB8332704D0 (en) * 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
EP0181793B1 (fr) * 1984-10-16 1988-07-27 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
US4789676A (en) * 1986-03-05 1988-12-06 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives, usefull as anxiolytic agents
EP0351283A1 (fr) * 1988-07-12 1990-01-17 Synthelabo Dérivés de [(pipéridinyl-4) méthyl]-2 dihydro-2,3 1H-isoindole et tétrahydro-2,3,4,5 1H-benzazépines, leur préparation et leur application en thérapeutique
FR2634207B1 (fr) * 1988-07-12 1990-09-07 Synthelabo Derives de ((piperidinyl-4)methyl) benzazepines, leur preparation et leur application en therapeutique
FR2635524B1 (fr) * 1988-08-19 1992-04-24 Adir Nouveaux derives de benzopyrrolidinone, leur procede de preparation et les compositions pharmaceutiques les renfermant
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
TW203049B (es) * 1990-04-13 1993-04-01 Yamanouchi Pharma Co Ltd
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
FR2679561A1 (fr) * 1991-07-26 1993-01-29 Schneider Marc Nouveaux derives de l'(indolyl-1) alkylamine substituee par une chaine presentant des groupements carbonyles conjugues a un noyau aromatique.
SE9103752D0 (sv) 1991-12-18 1991-12-18 Astra Ab New compounds
TW218875B (es) * 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
TW226019B (es) * 1992-03-23 1994-07-01 Sankyo Co
EP0572235A3 (en) * 1992-05-28 1994-06-01 Tanabe Seiyaku Co Beta-carboline derivatives with anticholecystoquinine activity
JPH08503213A (ja) * 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
PL176993B1 (pl) * 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
WO1995017423A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
CN1052730C (zh) * 1993-12-23 2000-05-24 诺沃挪第克公司 具有生长激素释放特性的化合物
GB9418326D0 (en) * 1994-09-12 1994-11-02 Lilly Industries Ltd Pharmaceutical compounds
ATE247114T1 (de) * 1994-09-12 2003-08-15 Lilly Co Eli Serotonergische modulatoren
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues

Also Published As

Publication number Publication date
HUP9603498A2 (hu) 1998-09-28
JPH09202784A (ja) 1997-08-05
KR970042503A (ko) 1997-07-24
IL119844A0 (en) 1997-03-18
DE69614491D1 (de) 2001-09-20
IL119844A (en) 2000-12-06
GB2308362A (en) 1997-06-25
NO307512B1 (no) 2000-04-17
AR010205A1 (es) 2000-06-07
CN1157822A (zh) 1997-08-27
GB9525963D0 (en) 1996-02-21
ZA9610589B (en) 1998-01-16
SG47206A1 (en) 1998-03-20
MX9606531A (es) 1997-06-28
PE26198A1 (es) 1998-05-27
EP0780388B1 (en) 2001-08-16
NO965448L (no) 1997-06-20
DK0780388T3 (da) 2001-10-08
HU9603498D0 (en) 1997-02-28
PT780388E (pt) 2001-12-28
CA2193039A1 (en) 1997-06-20
AU720711B2 (en) 2000-06-08
EP0780388A1 (en) 1997-06-25
NZ299959A (en) 1998-09-24
BR9606066A (pt) 1998-09-01
CA2193039C (en) 2006-04-04
CZ372296A3 (en) 1997-08-13
AU7546096A (en) 1997-06-26
TR199601018A1 (tr) 1997-07-21
PL317526A1 (en) 1997-06-23
ATE204273T1 (de) 2001-09-15
NO965448D0 (no) 1996-12-18
YU67096A (sh) 1999-03-04
HUP9603498A3 (en) 2001-04-28
US5773448A (en) 1998-06-30
DE69614491T2 (de) 2002-04-18

Similar Documents

Publication Publication Date Title
HUP9802323A2 (hu) Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
ES2197160T3 (es) Antagonistas fibronogeno bicicliclos.
ATE218141T1 (de) Erythromycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FI885569A (fi) Vattenloesliga kamptothecinanaloger.
BR9813279A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratar uma doença de um corpo vivo de animal incluindo um ser humano
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
ES8205755A1 (es) Procedimiento para la preparacion de nonapeptidos y decapep-tidos analogos a lhrh,utiles como antagonistas de lhrh
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
ATE9793T1 (de) 5-oxo- und 5-thioxoproline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2032749T3 (es) Acidos oxoftalazinil-aceticos heterociclicos.
ES2054826T3 (es) Peptidos con actividad inhibidora de colagenasa.
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
NO922185D0 (no) 1-metylkarbapenemderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som antibiotika
HUP9801838A2 (hu) Specifikus ingerlő aminosav antagonista indolszármazékok
ATE211474T1 (de) Galanthamin derivate, verfahren zu ihrer herstellung und ihre verwendung als medikamente
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
DE3583872D1 (de) Dihydropyridin-derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen, und verfahren zur herstellung dieser zusammensetzungen.
ES2059468T3 (es) Derivados imida, su produccion y uso.
FR2679555B1 (fr) Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ES2159693T3 (es) Ligandos 5ht1dalfa y 5ht2a.
ATE37872T1 (de) Phenylinden-derivate, ihre salze, und verfahren zu ihrer herstellung.
ATE45878T1 (de) Pharmazeutische praeparate enthaltend flavenoder thioflaven-derivate, deren verwendung, flavene und thioflavene und verfahren zu deren herstellung.
DE60021368D1 (de) Ppar-(gamma) agonisten zur behandlung von type ii diabetes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 780388

Country of ref document: ES